Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab with Chemoradiotherapy in Potentially Resectable Pancreatic Cancer
NCT05634564Phase 2Unknown
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Jun 2020
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in pancreatic cancer (PC), sponsored by Nanjing Drum-Tower Hospital. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05634564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05634564.